These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 27913060)

  • 1. Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-α use in females with immune mediated diseases; a systematic review and meta-analysis.
    Komaki F; Komaki Y; Micic D; Ido A; Sakuraba A
    J Autoimmun; 2017 Jan; 76():38-52. PubMed ID: 27913060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-Analysis of Pregnancy Outcomes after Exposure to TNF-α Inhibitors During Pregnancy for the Treatment of Arthritic Diseases.
    Mirdamadi K; Salinas T; Vali R; Papadimitropoulos M; Piquette-Miller M
    J Popul Ther Clin Pharmacol; 2018 Apr; 25(1):e53-e56. PubMed ID: 29949681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor necrosis factor-α therapy may not be safe during pregnancy in women with inflammatory bowel disease: an updated meta-analysis and systematic review.
    Huang W; Zhang X; Zhang L; Dai X; Chen H; Xie Q
    BMC Pregnancy Childbirth; 2024 Apr; 24(1):251. PubMed ID: 38589784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis.
    Mozaffari S; Abdolghaffari AH; Nikfar S; Abdollahi M
    Hum Exp Toxicol; 2015 May; 34(5):445-59. PubMed ID: 25378092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis.
    Komaki Y; Yamada A; Komaki F; Kudaravalli P; Micic D; Ido A; Sakuraba A
    J Autoimmun; 2017 May; 79():4-16. PubMed ID: 28209290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pregnancy and neonatal outcomes in women with immune mediated inflammatory diseases exposed to anti-tumor necrosis factor-α during pregnancy: A systemic review and meta-analysis.
    Barenbrug L; Groen MT; Hoentjen F; van Drongelen J; Reek JMPAVD; Joosten I; de Jong EMGJ; van der Molen RG
    J Autoimmun; 2021 Aug; 122():102676. PubMed ID: 34126302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Risk of Birth Defects for Infants Whose Mothers Are Treated With Anti-Tumor Necrosis Factor Agents During Pregnancy.
    Bröms G; Granath F; Ekbom A; Hellgren K; Pedersen L; Sørensen HT; Stephansson O; Kieler H
    Clin Gastroenterol Hepatol; 2016 Feb; 14(2):234-41.e1-5. PubMed ID: 26375613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-TNF-α Use During the Third Trimester of Pregnancy in Women with Moderate-severe Inflammatory Bowel Disease and the Risk of Preterm Birth and Low Birth Weight.
    Kammerlander H; Nielsen J; Knudsen T; Kjeldsen J; Friedman S; Nørgård BM
    Inflamm Bowel Dis; 2017 Nov; 23(11):1916-1923. PubMed ID: 28858070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effects of Active IBD During Pregnancy in the Era of Novel IBD Therapies.
    de Lima-Karagiannis A; Zelinkova-Detkova Z; van der Woude CJ
    Am J Gastroenterol; 2016 Sep; 111(9):1305-12. PubMed ID: 27349339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TNFα therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis.
    Narula N; Al-Dabbagh R; Dhillon A; Sands BE; Marshall JK
    Inflamm Bowel Dis; 2014 Oct; 20(10):1862-9. PubMed ID: 24983985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease.
    Casanova MJ; Chaparro M; Domènech E; Barreiro-de Acosta M; Bermejo F; Iglesias E; Gomollón F; Rodrigo L; Calvet X; Esteve M; García-Planella E; García-López S; Taxonera C; Calvo M; López M; Ginard D; Gómez-García M; Garrido E; Pérez-Calle JL; Beltrán B; Piqueras M; Saro C; Botella B; Dueñas C; Ponferrada A; Mañosa M; García-Sánchez V; Maté J; Gisbert JP
    Am J Gastroenterol; 2013 Mar; 108(3):433-40. PubMed ID: 23318480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study.
    Bortlik M; Machkova N; Duricova D; Malickova K; Hrdlicka L; Lukas M; Kohout P; Shonova O; Lukas M
    Scand J Gastroenterol; 2013 Aug; 48(8):951-8. PubMed ID: 23834232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-TNF treatment during pregnancy and birth outcomes: A population-based study from Denmark, Finland, and Sweden.
    Bröms G; Kieler H; Ekbom A; Gissler M; Hellgren K; Lahesmaa-Korpinen AM; Pedersen L; Schmitt-Egenolf M; Sørensen HT; Granath F
    Pharmacoepidemiol Drug Saf; 2020 Mar; 29(3):316-327. PubMed ID: 32020767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of TNF-α inhibitors during IBD pregnancy: a systematic review.
    Nielsen OH; Loftus EV; Jess T
    BMC Med; 2013 Jul; 11():174. PubMed ID: 23902720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety.
    de Lima A; Zelinkova Z; van der Ent C; Steegers EA; van der Woude CJ
    Gut; 2016 Aug; 65(8):1261-8. PubMed ID: 25966992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study.
    Weber-Schoendorfer C; Oppermann M; Wacker E; Bernard N; ; Beghin D; Cuppers-Maarschalkerweerd B; Richardson JL; Rothuizen LE; Pistelli A; Malm H; Eleftheriou G; Kennedy D; Kadioglu Duman M; Meister R; Schaefer C
    Br J Clin Pharmacol; 2015 Oct; 80(4):727-39. PubMed ID: 25808588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brief report: Risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune-mediated diseases in pregnancy.
    Cooper WO; Cheetham TC; Li DK; Stein CM; Callahan ST; Morgan TM; Shintani AK; Chen N; Griffin MR; Ray WA
    Arthritis Rheumatol; 2014 Feb; 66(2):444-50. PubMed ID: 24504818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous Anti-TNFα Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION).
    Luu M; Benzenine E; Doret M; Michiels C; Barkun A; Degand T; Quantin C; Bardou M
    Am J Gastroenterol; 2018 Nov; 113(11):1669-1677. PubMed ID: 29961771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of Disease Activity on Birth Outcomes in a Nationwide Cohort of Women with Moderate to Severe Inflammatory Bowel Disease.
    Kammerlander H; Nielsen J; Kjeldsen J; Knudsen T; Friedman S; Nørgård B
    Inflamm Bowel Dis; 2017 Jun; 23(6):1011-1018. PubMed ID: 28346274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Tumour Necrosis Factor α Therapies and Inflammatory Bowel Disease Pregnancy Outcomes: A Meta-analysis.
    Shihab Z; Yeomans ND; De Cruz P
    J Crohns Colitis; 2016 Aug; 10(8):979-88. PubMed ID: 26755733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.